Abstract
The non-vitamin K oral anticoagulants (NOACs) are set to replace vitamin K antagonists (principally warfarin), unfractionated heparin and low molecular weight heparin as the leading antithrombotic prophylaxis in several medical and surgical settings. As a group, NOACs have a better safety profile and at least an equivalent (and sometimes superior) efficacy profile than their comparator. The objective of this review is to provide the practitioner with a comprehensive, balanced and contemporary view of these drugs and their applications. More specifically, it focuses on the evidence base for their licences, use in clinical practice (such as in renal dysfunction, orthopaedic surgery, atrial fibrillation, and venous thromboembolism, and the effects of co-medications), responses to actual or perceived haemorrhage, and the role of the laboratory.
Keywords: NOACs, dabigatran, rivaroxaban, apixaban, edoxaban.
Current Vascular Pharmacology
Title:Non-Vitamin K Oral Anticoagulants (NOACs) A Review of Clinical Management and Laboratory Issues
Volume: 14 Issue: 3
Author(s): Andrew Blann
Affiliation:
Keywords: NOACs, dabigatran, rivaroxaban, apixaban, edoxaban.
Abstract: The non-vitamin K oral anticoagulants (NOACs) are set to replace vitamin K antagonists (principally warfarin), unfractionated heparin and low molecular weight heparin as the leading antithrombotic prophylaxis in several medical and surgical settings. As a group, NOACs have a better safety profile and at least an equivalent (and sometimes superior) efficacy profile than their comparator. The objective of this review is to provide the practitioner with a comprehensive, balanced and contemporary view of these drugs and their applications. More specifically, it focuses on the evidence base for their licences, use in clinical practice (such as in renal dysfunction, orthopaedic surgery, atrial fibrillation, and venous thromboembolism, and the effects of co-medications), responses to actual or perceived haemorrhage, and the role of the laboratory.
Export Options
About this article
Cite this article as:
Blann Andrew, Non-Vitamin K Oral Anticoagulants (NOACs) A Review of Clinical Management and Laboratory Issues, Current Vascular Pharmacology 2016; 14 (3) . https://dx.doi.org/10.2174/1570161113666150610093255
DOI https://dx.doi.org/10.2174/1570161113666150610093255 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Psychosocial Risk Factors and Ischemic Heart Disease: A New Perspective
Reviews on Recent Clinical Trials Towards a Better Understanding of Cardiac and Vascular Disease in Patients with Chronic Kidney Disease
Current Cardiology Reviews Effects of Oral L-Citrulline Supplementation on Lipoprotein Oxidation and Endothelial Dysfunction in Humans with Vasospastic Angina
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Biobanking in Atherosclerotic Disease, Opportunities and Pitfalls
Current Cardiology Reviews Soluble Amyloid-β Levels and Late-Life Depression
Current Pharmaceutical Design Considering Circadian Pattern of Blood Pressure in the Treatment of Hypertension via Chronotherapy: A Conducive or Maladroit Approach
Current Drug Targets A Survey on the Usage of Supplements in Canadian Patients Living with HIV
Current HIV Research Seek and Destroy: The Use of Natural Compounds for Targeting the Molecular Roots of Cancer
Current Drug Targets A Review of Macrolide Treatment of Atherosclerosis and Abdominal Aortic Aneurysms
Current Drug Targets - Infectious Disorders Myocardial Infarction. Pathological Relevance and Relationship with Coronary Risk Factors
Current Pharmaceutical Design The Pamela Study: Old and New Findings
Current Hypertension Reviews Diabetes Mellitus: Channeling Care through Cellular Discovery
Current Neurovascular Research Novel Agents Targeting Nitric Oxide
Current Vascular Pharmacology Risk and Benefit of Statins in Stroke Secondary Prevention
Current Vascular Pharmacology Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology
Current Medicinal Chemistry Expression and Function of MicroRNAs in Heart Disease
Current Drug Targets Casein Phosphopeptides in Oral Health - Chemistry and Clinical Applications
Current Pharmaceutical Design Biomarkers in Lone Atrial Fibrillation-An Additional ‘Fine Tuning’ of Risk?
Current Pharmaceutical Design Single Nucleotide Polymorphisms (SNPs): History, Biotechnological Outlook and Practical Applications
Current Pharmacogenomics Recent Advances in the Comprehension and the Management of Perioperative Systemic Host Response During Cardiopulmonary Bypass
Recent Patents on Cardiovascular Drug Discovery